Navigation Links
Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference
Date:11/8/2011

ith the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential, efficacy and safety of ADASUVE (Staccato loxapine). Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory appro
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: ... registered offering of common shares in the ... Offering, the Company issued 7,286,432 common shares at a ... of approximately $1.45 billion. On March 18, 2015, the ... a final prospectus supplement to its effective shelf registration ...
(Date:3/27/2015)... 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... today announced that they have entered into ... and proprietary sd-rxRNA® technology for use in ... has the potential to result in novel, ... that could be a significant step toward ...
(Date:3/27/2015)... , March 27, 2015  WebMD ... leading source of health information, today announced ... new National Action Plan for Combating ... Obama emphasized the urgency and importance of ... national and global health.    The ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... -- Weikang Bio-technology Group, Inc. (the "Company," "Weikang" or ... all of its management departments into the building it ... Chengde Street in the Daowai District of Harbin, the ... of the building. Mr. Yin Wang, the ...
... Dec. 27, 2011  PharmacoFore, Inc., a privately held biopharmaceutical ... equity financing from Founders Fund and the addition ... Board of Directors.   PharmacoFore uses innovative ... treating a variety of conditions related to the ...
Cached Medicine Technology:Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 2Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 3PharmacoFore, Inc. Secures $10 Million in Equity Financing From Founders Fund 2
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness ... Chesapeake Conference Center in Chesapeake, Virginia. Each year, ARDX ... women in the Hampton Roads region. The 2015 Women’s ... Women grow stronger through sharing their stories and learning ... the WWC™ theme is T-talk where we will share a ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Servpro ... , this week released a report about the link ... of asthma sufferers, and according to recent medical research, ... , According to the Environmental Protection Agency, people with ... reactions. Breathing in mold may trigger asthma attacks for ...
(Date:3/27/2015)... The Monogamy Method - a new ... Jason Rogers has just been released to the public ... surrounding the course's launch has caught the attention of ... review of the new program. , "Many women report ... suddenly start pulling away or expressing interest in other ...
(Date:3/27/2015)... 2015 In her mid-forties and with a ... working, Monica K. arrived at JET Uniform & Supply ... defensive and scared. The owners and staff at JET, which ... (EPSS) to offer jobs to challenged residents like Monica, were ... willingness to begin with the end in mind,” says Stephen ...
(Date:3/27/2015)... New York, New York (PRWEB) March 27, 2015 ... lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that allege the statin medication ... 2 diabetes has granted Pfizer Inc.’s Motion to Dismiss ... proceeding. According to a Case Management Order issued in ... March 23rd, the Court determined that the dismissals were ...
Breaking Medicine News(10 mins):Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
... 24 Sopherion Therapeutics, LLC, a biopharmaceutical company ... therapies, has announced the appointment of Dr. Marcel ... Affairs. Prior to joining Sopherion, Dr. Rozencweig was ... and a member of the Sopherion Protocol Development ...
... ON, Feb. 24 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: ... research and development of drug products delivered to and ... delivery technologies, today announced that Nuvo,s INSIGHT(TM) platform, developed ... fqubed, Inc., has been selected as one of four ...
... of Nearly 106 Million PrescriptionsStrong 2009 EPS Guidance ReaffirmedFourth-Quarter ... percent to $0.54 from $0.38 in 2007 , - ... from the 2003 spin-off, increased 37.2 percent to $0.59 ... volume of 26.7 million increased 9.4 percent from 2007 ...
... a medical imaging and diagnostic Company launches new Physician Billing Services ... billing services as part of its commitment to synergistically diversify the ... ... 2009 -- Bederra Corporation (Pink Sheets: BEDA), a medical ...
... 24 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... and year ended December 31, 2008.(Logo: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO )For ... loss of $33.4 million, or $0.91 per share, compared ... per share, in the fourth quarter of 2007. Weighted ...
... Healthcare Workers from Hazardous Drug ExposureCOLUMBUS, Ohio, Feb. 24 ... the safe handling of hazardous drugs in the healthcare ... Safe Handling Awareness Month with Monday, April 20, 2009 ... The proclamation of National Safe Handling Awareness Month ...
Cached Medicine News:Health News:Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 2Health News:Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 2Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 3Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 4Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 5Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 6Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 7Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 8Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 9Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 10Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 11Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 12Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 13Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 14Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 15Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 16Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 17Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 18Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 19Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 20Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 21Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 22Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 23Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 24Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 25Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 26Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 27Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 28Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 29Health News:Medco Delivers Fourth-Quarter GAAP Diluted EPS Growth of 42 Percent; 2008 Full-Year GAAP Diluted EPS Growth of 31 Percent 30Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 2Health News:Bederra Corporation Launches New Billing Services Division Expected to Add up to $500,000 in Revenue 3Health News:Rigel Announces Fourth Quarter and Year End 2008 Financial Results 2
... and probe system used together to quantify ... based system is a sandwich nucleic acid ... for RNA detection and quantification, by amplifying ... technology. Branched DNA allows immediate quantification of ...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits....
...
For the qualitative detection of Infectious mononucleosis IgM heterophile antibodies in human whole blood, serum and plasma specimens....
Medicine Products: